Back to search results

CDR132L for Heart Failure with Preserved Ejection Fraction

This study is looking at how CDR132L, a potential new treatment, affects the heart's structure and function in people with heart failure. You might be able to join if you are between 40 and 84 years old and have symptomatic chronic heart failure (when your heart can't pump enough blood to meet your body's needs) that has been diagnosed for at least 90 days. Participants will receive either CDR132L or a placebo (a treatment with no active medicine) through an IV every four weeks. The main goal is to see how a specific marker, microRNA-132-3p, changes over 24 weeks. The study plans to enroll 200 people, but its current status is unclear.

Study design
This is an interventional study comparing different doses of CDR132L with a placebo. Participants will be randomly assigned to receive either CDR132L or placebo, and the study plans to enroll 200 people.
What's involved
You would receive either CDR132L or placebo intravenously once every 4 weeks. The study will last for about 60 weeks.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured from baseline to week 24, and the study will last for about 60 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06979362

A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

Recruiting
PHASE2Ages 40–84InterventionalTreatment
Novo Nordisk A/S
~200 participants
Updated 2026-08-05 on ClinicalTrials.gov
What's tested:CDR132LPlacebo

At a glance

Recruiting sites
71 of 117 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Main phase: Change in normalised microRNA-132-3p (miR-132)
Measured over From baseline to week 24

Conditions

Heart Failure

Explore related trials

Heart FailureN-Terminal Fragment Brain Natriuretic Protein

NCT06979362

Where you'd take part

This study runs at 117 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • 1 Wojskowy Szpital Kliniczny z Poliklinika SPZOZ

    Lublin, Lublin Voivodeship, Polandno site contact published

    Recruiting

  • 4 Wojskowy Szpital Kliniczny Z Poliklinika Samodzielny Publiczny Zaklad Opieki Zdrowotnej We Wroclawiu

    Wroclaw, Lower Silesian Voivodeship, Polandno site contact published

    Recruiting

  • AdventHealth Orlando

    Orlando, Floridano site contact published

    Not yet recruiting

  • All India Institute of Medical Sciences (AIIMS), Nagpur

    Nagpur, Maharashtra, Indiano site contact published

    Recruiting

  • All India Institute of Medical Sciences (AIIMS), Nagpur

    Nagpur, Maharashtra, Indiano site contact published

    Not yet recruiting

  • Amarillo Medical Specialists

    Amarillo, Texasno site contact published

    Not yet recruiting

  • American Heart of Poland S.A.

    Bielsko-Biala, Polandno site contact published

    Recruiting

  • Apollo Hospital Chennai

    Chennai, Tamil Nadu, Indiano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Clinical Transparency (dept. 2834) · STUDY_DIRECTOR · Novo Nordisk A/S

Who to contact

Novo Nordisk
[email protected]
(+1) 866-867-7178
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 40-84 years (both inclusive) at the time of signing the informed consent
Documented symptomatic chronic heart failure (HF) diagnosed greater than or equal to (≥) 90 days prior to screening with at least weekly need for oral diuretic treatment, and New York Heart Association class II-III at screening
Clinically stable and on optimised doses and unchanged drug classes of guideline-directed HF therapy ≥45 days prior to randomisation
Left ventricular ejection fraction ≥50% as assessed by echocardiography at screening, measured by central laboratory
Left ventricular hypertrophy assessed by echocardiography at screening measured by central laboratory with any of the following:
Body mass index 18.5-40 kilogram per square meter (kg/m\^2) (both inclusive) and body weight less than or equal to (≤) 140 kilogram (kg). Body mass index is calculated in the electronic case report form based on height and body weight at the screening visit (visit 1)
NT-proBNP ≥300 picograms per milliliter (pg/mL); NT-proBNP ≥600 pg/mL if atrial fibrillation/flutter is present at time of screening, measured by central laboratory

Exclusion

Estimated glomerular filtration rate lesser than (\<) 30 milliliter per minute (mL/min)/1.73 square meter (m\^2) at time of screening, measured by central laboratory
Participants with an episode of acute kidney failure or acute kidney injury, at the discretion of the investigator, within 90 days prior to randomisation
Myocardial infarction, unstable angina pectoris or HF hospitalisation within 30 days prior to screening
Participants receiving intravenous HF medications within 45 days prior to randomisation
Participants with CRT, pacemaker or implantable cardioverter-defibrillator
Planned coronary revascularisation, pacemaker/cardioverter-defibrillator/CRT implantation, ablation of cardiac arrythmias and valve repair/replacement at the time of randomisation
Stroke or transient ischemic attack within 12 months prior to randomisation
Participants with potential disruption of the blood-brain barrier (e.g., multiple sclerosis), in the opinion of the investigator
Known history of severe liver disease and/or alanine aminotransferase or aspartate aminotransferase \>2.5 x upper limit of normal at screening, measured by central laboratory
Known genetic (or highly suspected due to family history) cause of increased cardiac mass (including dilated cardiomyopathy, Fabry disease and likely pathogenic or pathogenic variants within hypertrophic cardiomyopathy \[HCM\]).
Participants with suspected or diagnosed cardiac amyloidosis or sarcoidosis.

What this trial measures

  • Main phase: Change in normalised microRNA-132-3p (miR-132)From baseline to week 24

    Measured as ratio to baseline.